The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1

REFERENCES

1. 1.↵
   2. Scherfler C,
   3. Schwarz J,
   4. Antonini A, et al

   . Role of DAT-SPECT in the diagnostic work-up of parkinsonism. Mov Disord 2007;22:1229–38

   CrossRefPubMed
2. 2.↵
   2. Catafau AM,
   3. Tolosa E

   . Impact of dopamine transporter SPECT using ¹²³I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 2004;19:1175–82

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Hughes AJ,
   3. Daniel SE,
   4. Kilford L, et al

   . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84

   Abstract/FREE Full Text
4. 4.↵
   2. Booij J,
   3. Tissingh G,
   4. Winogrodzka A, et al

   . Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171–82

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Seppi K

   . MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. Parkinsonism Relat Disord 2007;13:S400–05

   CrossRefPubMed
6. 6.↵
   2. Sitburana O,
   3. Ondo WG

   . Brain magnetic resonance imaging (MRI) in parkinsonian disorders. Parkinsonism Rel Disord 2009;15:165–74

   CrossRef
7. 7.↵
   2. Kaufman MJ,
   3. Madras BK

   . Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43–49

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Melikian HG,
   3. Buckley KM

   . Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 1999;19:7699–710

   Abstract/FREE Full Text
9. 9.↵
   2. Garcia BG,
   3. Wei Y,
   4. Moron JA, et al

   . Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol 2005;68:102–09

   Abstract/FREE Full Text
10. 10.↵
    2. Fahn S,
    3. Oakes D,
    4. Shoulson I, et al

    . Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498–508

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Neumeyer JL,
    3. Wang S,
    4. Gao Y, et al

    . N-omega-fluoroalkyl analogues of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558–61

    CrossRefPubMed
12. 12.↵
    2. Booij J,
    3. Andringa G,
    4. Rijks LJ, et al

    . ¹²³I-FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183–90

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Mozley PD,
    3. Schneider JS,
    4. Acton PD, et al

    . Binding of [^99mTc-]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000;41:584–89

    Abstract/FREE Full Text
14. 14.↵
    2. Kim HJ,
    3. Im JH,
    4. Yang SO, et al

    . Imaging and quantification of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997;38:1703–11

    Abstract/FREE Full Text
15. 15.↵
    2. Booij J,
    3. Hemelaar TG,
    4. Speelman JD, et al

    . One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [¹²³I]FPCIT SPECT. J Nucl Med 1999;40:753–61

    Abstract/FREE Full Text
16. 16.↵
    2. Hughes AJ,
    3. Daniel SE,
    4. Ben-Shlomo Y, et al

    . The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–70

    Abstract/FREE Full Text
17. 17.↵
    2. Marshall VL,
    3. Reininger CB,
    4. Marquardt M, et al

    . Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500–08

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Kupsch AR,
    3. Bajaj N,
    4. Weiland F, et al

    . Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry 2012;83:620–28

    Abstract/FREE Full Text
19. 19.↵
    2. Acton PD,
    3. Newberg A,
    4. Ploessl K, et al

    . Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [^99mTc]Trodat-1 and SPECT. Phys Med Biol 2006;51:575–85

    CrossRefPubMed
20. 20.↵
    2. Djang DS,
    3. Janssen MJ,
    4. Bohnen N, et al

    . SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012;53:154–63

    FREE Full Text
21. 21.↵
    2. Yekhlef F,
    3. Ballan G,
    4. Macia F, et al

    . Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003;110:151–69

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Savoiardo M

    . Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003;24(Suppl 1):S35–37

    CrossRefPubMed
23. 23.↵
    2. Aquino D,
    3. Contarino V,
    4. Albanese A, et al

    . Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 2014;35:753–58

    CrossRefPubMed
24. 24.↵
    2. Nagano-Saito A,
    3. Washimi Y,
    4. Arahata Y, et al

    . Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224–29

    CrossRef
25. 25.↵
    2. Scherfler C,
    3. Schocke MF,
    4. Seppi K, et al

    . Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 2006;129:538–42

    Abstract/FREE Full Text
26. 26.↵
    2. Clarke CE,
    3. Lowry M

    . Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001;8:573–77

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Gaenslen A,
    3. Unmuth B,
    4. Godau J, et al

    . The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008;7:417–24

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Berg D,
    3. Godau J,
    4. Walter U

    . Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044–55

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Morrish PK,
    3. Rakshi JS,
    4. Bailey DL, et al

    . Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [¹⁸F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314–19

    Abstract/FREE Full Text
30. 30.↵
    2. Brooks DJ,
    3. Salmon EP,
    4. Mathias CJ, et al

    . The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539–52

    Abstract/FREE Full Text
31. 31.↵
    2. Khan NL,
    3. Valente EM,
    4. Bentivoglio AR, et al

    . Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002;52:849–53

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Ghaemi M,
    3. Hilker R,
    4. Rudolf J, et al

    . Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET. J Neurol Neurosurg Psychiatry 2002;73:517–23

    Abstract/FREE Full Text
33. 33.↵
    2. Antonini A,
    3. Leenders KL,
    4. Vontobel P, et al

    . Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187–95

    Abstract/FREE Full Text
34. 34.↵
    2. Innis RB,
    3. Seibyl JP,
    4. Scanley BE, et al

    . Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 1993;90:11965–69

    Abstract/FREE Full Text
35. 35.↵
    2. Brücke T,
    3. Asenbaum S,
    4. Pirker W, et al

    . Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24

    CrossRefPubMed
36. 36.↵
    2. Varrone A,
    3. Pellecchia MT,
    4. Amboni M, et al

    . Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology 2004;63:2097–103

    CrossRef
37. 37.↵
    2. Benamer TS,
    3. Patterson J,
    4. Grosset DG, et al

    . Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³I]-FP-CIT SPECT imaging: the [¹²³I]-FP-CIT study group. Mov Disord 2000;15:503–10

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Vlaar AM,
    3. van Kroonenburgh MJ,
    4. Kessels AG, et al

    . Meta-analysis of the literature on the diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27

    CrossRefPubMed
39. 39.↵
    Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653–61

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Bernheimer H,
    3. Birkmayer W,
    4. Hornykiewicz O, et al

    . Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415–55

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Bezard E,
    3. Dovero S,
    4. Prunier C, et al

    . Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4phenyl-1,2,3,5-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853–61

    Abstract/FREE Full Text
42. 42.↵
    2. Tissingh G,
    3. Bergmans P,
    4. Booij J, et al

    . Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 1998;245:14–20

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Ponsen MM,
    3. Stoffers D,
    4. Wolters EC, et al

    . Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81:396–99

    Abstract/FREE Full Text
44. 44.↵
    2. van Dyck CH,
    3. Seibyl JP,
    4. Malison RT, et al

    . Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med 1995;36:1175–81

    Abstract/FREE Full Text
45. 45.↵
    2. Ravina B,
    3. Eidelberg D,
    4. Ahlskog JE, et al

    . The role of radiotracer imaging in Parkinson's disease. Neurology 2005;64:208–15

    CrossRef